BioSpace News Archive

LUCA Science Inc. and Kyowa Kirin Co., Ltd. are pleased to announce they have entered into a research collaboration agreement on the treatment of mitochondrial diseases using platform of an innovative mitochondrial modality.

Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, provided updated clinical data from the ongoing AAVance phase 2/3 clinical trial with the investigational gene therapy LYS-SAF302 for the treatment of MPS IIIA during the 25th Annual Meeting of the ASGCT in Washington, DC.

Keros Therapeutics, Inc. announced preliminary topline results from Part 1 of its Phase 1 clinical trial evaluating single and multiple ascending doses of KER-012 in healthy postmenopausal volunteers.

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, announced the appointment of Professor John R.B. Perry as its Vice President, Human Genetics.

Editas Medicine, Inc., a leading genome editing company, will present data later on its SLEEK gene editing technology during the New Gene Editing Technologies and Applications Session at the 25th Annual Meeting of the American Society of Gene and Cell Therapy being held in Washington, D.C., and virtually, May 16 – 19, 2022.

SQZ Biotechnologies announced that the company’s first generation, integrated point-of-care cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specifications relative to current clean room-based processes used in clinical development.

Arecor Therapeutics plc, the biopharmaceutical group advancing ’s therapies to enable healthier lives, today announces that it will host a key opinion leader webinar entitled “The Need for Concentrated and Rapid Acting Insulin Treatments in Diabetes Care”, on Thursday 26 May, 2022, at 15:00-16:30 BST.

Instil Bio, Inc. today announced results of genomic and correlative analyses in a cohort of patients with metastatic melanoma treated with TILs manufactured by Instil (ORR of 67% in 14/21 patients).

Luzsana to co-develop medicines with parent company Hengrui Pharma and commercialize in North America, Europe and Japan.

Chemomab Therapeutics Ltd. announced that management will participate in the virtual portion of the H.C. Wainwright Global Investment Conference, which will take place May 23-26, 2022.